Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Realcan Pharmaceutical Group CoSZSE:002589 -3.64%45 EBITDA Margin % is 4.20% as of Mar. 2026, which is 28% below its 10-year median of 5.84. GuruFocus rates SZSE:002589 with a GF Score™ of 45/100 and a GF Value™ of ¥2.38 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 117 Medical Distribution companies, Realcan Pharmaceutical Group Co ranks worse than 72.65% on this metric.
Realcan Pharmaceutical Group Co (SZSE:002589) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Realcan Pharmaceutical Group Co EBITDA Margin % Related Terms
Realcan Pharmaceutical Group Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Realcan Pharmaceutical Group Co EBITDA Margin % Chart
SZSE:002589 vs MCK, CAH, COR: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Realcan Pharmaceutical Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Realcan Pharmaceutical Group Co EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Realcan Pharmaceutical Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Realcan Pharmaceutical Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Realcan Pharmaceutical Group Co (SZSE:002589) has a EBITDA Margin % of 4.20% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Realcan Pharmaceutical Group Co and its competitors. This is 28% below median its historical median of 5.84. According to the industry distribution chart, Realcan Pharmaceutical Group Co ranks #85 out of 117 companies in the Medical Distribution industry, placing it in the top 72.6%.
Is Realcan Pharmaceutical Group Co's EBITDA Margin % too high?
Realcan Pharmaceutical Group Co's current EBITDA Margin % of 4.20% is 28% below median its 10-year median of 5.84. The Medical Distribution industry median EBITDA Margin % is 4.20. Realcan Pharmaceutical Group Co's value of 4.20% is 0% at this industry median. Based on the distribution chart, Realcan Pharmaceutical Group Co ranks #85 out of 117 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Realcan Pharmaceutical Group Co has a GF Score™ of 45/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Realcan Pharmaceutical Group Co's EBITDA Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Realcan Pharmaceutical Group Co ranks #85 out of 117 companies for EBITDA Margin %. This places Realcan Pharmaceutical Group Co in the lower half of its industry. The industry median EBITDA Margin % is 4.20. Realcan Pharmaceutical Group Co's value of 4.20% is 0% at this benchmark. While the company's 10-year median is 5.84 vs. the industry median of 4.20, Realcan Pharmaceutical Group Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.20, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Realcan Pharmaceutical Group Co's current EBITDA Margin % of 4.20% is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Realcan Pharmaceutical Group Co and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Realcan Pharmaceutical Group Co's current EBITDA Margin % is 4.20%, which is 28% below median its own 10-year median of 5.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Realcan Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Realcan Pharmaceutical Group Co (SZSE:002589) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥2.38, compared to a current price of ¥2.65 — trading 11.3% above its estimated fair value. The current EBITDA Margin % is 4.20%, which is 28% below median its 10-year median of 5.84 and 0% at the Medical Distribution industry median of 4.20. Realcan Pharmaceutical Group Co's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Realcan Pharmaceutical Group Co (SZSE:002589), the current EBITDA Margin % is 4.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Realcan Pharmaceutical Group Co (SZSE:002589) Overvalued in 2026?
Based on GuruFocus' analysis, Realcan Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥2.65 is trading 11.3% above its estimated GF Value™ of ¥2.38.
GuruFocus considers Realcan Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for SZSE:002589:
EBITDA Margin %: 4.20% (28% below median its 10-year median of 5.84)
GF Value™: ¥2.38 vs. price of ¥2.65 (11.3% above fair value)
Industry Position: 0% at the Medical Distribution median (#85 of 117)
No single metric tells the full story. See the SZSE:002589 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Realcan Pharmaceutical Group Co Business Description
Realcan Pharmaceutical Group Co Ltd is a Chinese company engaged in direct pharmaceuticals distribution services. The company's main business is divided into the Drug, vaccine, medical device circulation service; Medical industry third-party logistics; Medical information service; Medical logistics service; Chinese medicine plate; Hospital management sector; Medical industry research and development production sector; and Medical industry financial sector.
45GF Score
Get the complete analysis for SZSE:002589
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:002589 has been successfully added to your 
